Clinical Scorecard: Investigating the Molecular Pathways of Suxiao Jiuxin Pill in Reducing Inflammatory Responses Following Acute Myocardial Infarction: An Integrated Study Using Network Pharmacology, Mendelian Randomization, and Experimental Approaches

At a Glance

Key Highlights

• Suxiao Jiuxin Pill (SJP) shows potential in managing acute myocardial infarction.
• Key target genes NAMPT and FOS were identified as significantly upregulated in AMI.
• SJP ameliorated cardiac function and reduced inflammatory responses in MI rat models.
• Network pharmacology and Mendelian randomization were utilized to elucidate mechanisms.
• SJP's traditional use in Chinese medicine supports its role in cardiovascular health.

Guideline-Based Recommendations

Diagnosis

• Utilize transcriptome sequencing data for identifying AMI-related biomarkers.

Management

• Consider SJP as a complementary therapy in AMI management.

Monitoring & Follow-up

• Assess inflammatory factor expression and cardiac function post-treatment.

Risks

• Monitor for potential side effects associated with traditional Chinese medicine.

Patient & Prescribing Data

Individuals diagnosed with acute myocardial infarction.

SJP may enhance hemodynamics and reduce inflammatory reactions.

Clinical Best Practices

• Integrate traditional Chinese medicine with modern pharmacological approaches.
• Utilize network pharmacology for exploring multi-target therapies.

Related Resources & Content

• Gene Expression Omnibus (GEO)